Amadix - About the company
Amadix is a series A company based in Madrid (Spain), founded in 2010. It operates as a Provider of diagnostic tools to support personalized cancer treatment. Amadix has raised $6.87M in funding from Alentia. The company has 194 active competitors, including 64 funded and 41 that have exited. Its top competitors include companies like Guardant Health, Biodesix and BillionToOne.
Company Details
Provider of diagnostic tools to support personalized cancer treatment. The company has developed prognostic, diagnostic, and predictive tests for lung cancer, colorectal cancer, and prostate cancer. Its colon cancer test ColoFast is a blood-based miRNA test for early detection of colon cancer. It is also developing DiagnoLung which is a blood-based ELISA test that measures the level of three protein biomarkers to screen high-risk patients for non-small-cell lung cancer.
- Website
- amadix.com
- Social
- Email ID
- *****@amadix.com
- Phone Number
- +34 **********
Key Metrics
Founded Year
2010
Location
Madrid, Spain
Stage
Series A
Total Funding
$6.87M in 9 rounds
Latest Funding Round
Ranked
55th among 194 active competitors
Employee Count
46 as on Jun 30, 2026
Sign up to download Amadix's company profile
Amadix's funding and investors
Amadix has raised a total funding of $6.87M over 9 rounds. Its first funding round was on Feb 10, 2013. Its latest funding round was a Venture Debt round on Feb 14, 2025 for $*****. 1 investor participated in its latest round. Amadix has 10 institutional investors.
Here is the list of recent funding rounds of Amadix:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 14, 2025 | 7536233 | Venture Debt | 2862224 | 7219045 | 6074364 | 5877455 |
Aug 01, 2022 | 5746117 | Grant (prize money) | 6912395 | 2417646 | 9250954 | |
Jun 30, 2021 | 8799528 | Grant (prize money) | 6966631 | 9935246 | 4822261 |
Access funding benchmarks and valuations. Sign up today!View details of Amadix's funding rounds and investors
Amadix's founders and board of directors
Founder? Claim ProfileAmadix's employee count trend
Amadix has 46 employees as of Jun 26. Here is Amadix's employee count trend over the years:
Uncover Amadix's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Amadix's Competitors and alternates
Top competitors of Amadix include Guardant Health, Biodesix and BillionToOne. Here is the list of Top 10 competitors of Amadix, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 79/100 | |
2nd |  Biodesix 2005, Boulder (United States), Public | Developer of diagnostics assays for the detection of cancer | $200M | 75/100 | |
3rd | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
4th | Delfi Diagnostics 2019, Baltimore (United States), Series B | Provider of DNA sequencing for cancer detection | $332M | 68/100 | |
5th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
6th | _1559800772180.png?devicePixelRatio=2&height=30&width=30){kind=logo} Naveris 2017, Waltham (United States), Acquired | Provider of blood tests for early cancer detection | $68.5M | 66/100 | |
7th |  OncoCyte 2009, Irvine (United States), Public | Developer of non-invasive diagnostic tests solutions for the treatment of cancer | $15.3M | 66/100 | |
8th | Scipher Medicine 2014, Waltham (United States), Series D | Provider of precision medicine based on liquid biopsy test | $233M | 65/100 | |
9th | Saga Diagnostics 2016, Morrisville (United States), Acquired | Provider of tests for detection and analysis of circulating tumor DNA | $17.9M | 64/100 | |
10th | PrognomiQ 2020, San Mateo (United States), Series D | Developer of tests for the detection and treatment of cancer and other diseases | $135M | 63/100 | |
55th | Provider of diagnostic tools to support personalized cancer treatment | $6.87M | 43/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Amadix's competitors? Click here to see the top ones
Amadix's Investments and acquisitions
Amadix has made no investments or acquisitions yet.
News related to Amadix
•
EIT Health invests €1.2 million in Amadix's MORESCREEN projectEl Referente•May 19, 2025•Amadix, EIT Health
•
•
The EIB finances Amadix with 15 million eurosCastilla Leon Economic•Feb 10, 2025•European Investment Bank, Amadix
•
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Amadix
Explore our recently published companies
- Sum Technology - Petaling Jaya based, 2013 founded, Public company
- Rezna - United States based, 2026 founded, Unfunded company
- Moerkantheide - Unfunded company
- Gebaeudereinigung-Jasarov - Unfunded company
- Kosmetikstudio-Windsbach - Unfunded company
- Hammerundneuderth - Unfunded company
